UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (Date of earliest event reported): March 3, 2011
Valeant Pharmaceuticals International, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Canada
|
|
001-14956
|
|
98-0448205 |
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
7150 Mississauga Road
|
|
|
|
|
Mississauga, Ontario
|
|
|
|
|
Canada
|
|
|
|
L5N 8M5 |
(Address of principal executive offices)
|
|
|
|
(Zip Code) |
(905) 286-3000
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 8.01 Other Events.
On March 3, 2011, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) issued a press
release announcing that Valeant Pharmaceuticals International, its wholly owned indirect
subsidiary, has priced its offering of $950 million aggregate principal amount of its 6.500% Senior
Notes due 2016 and $550 million aggregate principal amount of its 7.250% Senior Notes due 2022. A
copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press Release announcing the pricing of the offering, dated March 3, 2011 |